Health Care · Pharmaceutical Preparations · Nasdaq · CIK 944809 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $1.37Day −17.27%Mkt cap $1.0B1Y +1.1%Off 52W high −21.1%Vol (1Y) 54.0%
Daily closing price, split-adjusted to the current basis; 3y shown of 5,294 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest4.5% of sh out |
| Days to cover13.0d |
| 13F net flow (QoQ)−0.02% |
| Top-10 13F concentration77.5% |
| Next report (est.)2026-10-27 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$587.9M |
| Earnings (TTM)-$72.9M |
| ROE−17.1% |
| Net margin−37.2% |
| ROIC−7.1% |
| Debt / equity0.27× |
| Sales growth 3Y−15.5% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+8.3% |
| 1Y+1.1% |
| 3Y−26.6% |
| 5Y−63.4% |
| 10Y−86.3% |
| Since incept. (ann.)+6.3% |
Total return through 2026-07-29 · series begins 2005-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)54.0% |
| Ann. volatility (3Y)53.8% |
| Sharpe (1Y)0.28 |
| Sharpe (3Y)0.09 |
| Max drawdown (1Y)−30.4% |
| Max drawdown (3Y)−56.5% |
| Beta (3Y vs SPY)1.15 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Rubric Capital Management LP | 47.8M | $54M | 6.30% | +0.0% |
| BlackRock, Inc. | 36.2M | $41M | 4.77% | +4.0% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 14.8M | $17M | 1.95% | new |
| VANGUARD CAPITAL MANAGEMENT LLC | 14.5M | $17M | 1.91% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 11.3M | $13M | 1.49% | +2.2% |
| STATE STREET CORP | 9.5M | $11M | 1.25% | +6.1% |
| GOLDMAN SACHS GROUP INC | 7.7M | $9M | 1.01% | +28.2% |
| UBS Group AG | 6.1M | $7M | 0.80% | +13.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-06-30 | 2026-07-27 | −$0.01 | — | $163.6M | +4.3% |
| 2026-03-31 | 2026-04-28 | −$0.07 | — | $124.2M | −17.2% |
| 2025-12-31 | 2026-02-26 | −$0.04 | −500.0% | $148.5M | −19.2% |
| 2025-09-30 | 2025-10-29 | $0.03 | +0.0% | $151.7M | −12.6% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-27 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
US 72% · CL 10% · IE 8% · ES 4% · MX 4%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
